Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
Event Date: Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) […]
Read MoreCrinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Event Date: Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing’s syndrome study SAN […]
Read MoreCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
Event Date: SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY. Management will be available for 1×1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging […]
Read MoreCrinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Event Date: PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel […]
Read MoreCrinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Event Date: PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics’ first regulatory approval outside of the U.S., with first launch planned for Germany and Austria […]
Read MoreCrinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Event Date: Crinetics will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 pm ET to discuss financial results and provide a business update.
Read MoreCrinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Event Date: Crinetics announces the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults.
Read MoreCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Event Date: Crinetics reports financial results for the fourth quarter and full year 2025. Company management will hold a live conference call and webcast on Thursday, February 26 at 4:30 PM ET.
Read MoreCrinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
Event Date: Crinetics announced that company management will participate in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference in Boston, Massachusetts, and the Leerink Annual Global Healthcare Conference in Miami, Florida.
Read MoreCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Event Date: Crinetics announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes.
Read MorePlease click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
